At BioNTech, we believe that the immune system is the fundamental driver for therapeutic success in cancer, infectious diseases, and other serious diseases.As immune engineers, we have a deep understanding of the mechanisms that enable the immune system to effectively recognize both internal threats ...
For decades, most researchers overlooked messenger RNA (mRNA) because it was considered far too unstable, and no proper solution existed to administer or guide it to the right cells in the body. In early research, it was difficult to achieve the desired levels of immune response and the produ...
Target NY-ESO-1, MAGE-A3, tyrosinase, TPTE Indications Advanced melanoma Phase 2 This randomized Phase 2 clinical trial evaluates the efficacy and safety of BNT111 in combination with cemiplimab, an anti-PD-1 monoclonal antibody, in patients with anti-PD-(L)1 refractory/relapsed, unresectable...
About usAbout TipRanksContact UsCareersReviews Working With TipRanksEnterprise SolutionsTop Online BrokersBecome an AffiliateTipRanks News Wire PlansPlans & PricingSmart Investor NewsletterSmart Dividend NewsletterAPI for Institutions Real Estate Opportunities ArrivedEquityMultiple Find Us on Disclaimer: The ...
(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 year...
(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for individuals 12 years and older and granted emergency use authorization for ...
, sa news editor 2 comments biontech se ( nasdaq: bntx ) has priced its initial public offering of 10m american depositary shares, each representing one ordinary share at $15.00 per ads, for gross proceeds of $150m. underwriters over-allotment is an additional 1.5m adss. the adss are...
(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of the mRNA vaccine, BNT162b2, against COVID-19 in individuals 16 years of age or older. The vaccine is now authorized under an ...
(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees ...
(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circul...